Table 1.
Demographic and clinical characteristics of prostate cancer patients in the three studies.
| TCGA (n= 475) |
Fred Hutch (n= 458) |
Canada ICGC (n= 236) |
p-value | ||
|---|---|---|---|---|---|
| Age | Median (25%, 75%) | 62 (57, 67) | 59 (53, 63) | 62 (59, 67) | 4.82×10−16 |
| Race | Caucasian | 405 (85%) | 430 (94%) | 226 (95%) | |
| African American | 58 (12%) | 28 (6%) | 6 (3%) | 3.66×10−7 | |
| Asian | 12 (3%) | 0 (0%) | 4 (2%) | ||
| Gleason Score | <= 6 | 41 (9%) | 217 (47%) | 21 (9%) | |
| 7 (3+4) | 146 (31%) | 166 (36%) | 137 (58%) | <1.0×10−16 | |
| 7 (4+3) | 97 (20%) | 41 (9%) | 58 (25%) | ||
| 8–10 | 191 (40%) | 34 (7%) | 17 (7%) | ||
| Missing | 0 (0%) | 0 | 3 (1%) | ||
| PSA (ng/mL) | <4 | 50 (11%) | 70 (15%) | 24 (10%) | |
| 4–10 | 264 (56%) | 274 (60%) | 155 (66%) | 2.84×10−8 | |
| 10–20 | 93 (20%) | 60 (13%) | 56 (24%) | ||
| ≥20 | 53 (11%) | 26 (6%) | 1 (0.4%) | ||
| Missing | 15 (3%) | 28 (6%) | 0 (0%） | ||
| Stage | Local/T2 | 178 (37%) | 312 (68%) | 114 (48%) | |
| Regional/T3 | 211 (44%) | 146 (32%) | 102 (43%) | <1.0×10−16 | |
| T4/N1 | 80 (17%) | 0 (0%) | 0 (0%) | ||
| Missing | 6 (1%) | 0 (0%) | 20 (8%) | ||
| Subtype | 1 | 137 (29%) | 123 (27%) | 21 (9%) | |
| 2 | 143 (30%) | 210 (46%) | 77 (33%) | <1.0×10−16 | |
| 3 | 109 (23%) | 97 (21%) | 97 (41%) | ||
| 4 | 86 (18%) | 28 (6%) | 41 (17%) |